Ọrịa cancer akpa ume ka bụ ihe ịma aka ahụike zuru ụwa ọnụ, ọkwa dịka ọrịa kansa nke abụọ a na-achọpụtakarị. Na 2020 naanị, enwere ihe karịrị nde 2.2 ọhụrụ n'ụwa niile. Ọrịa cancer akpa ume na-abụghị obere cell (NSCLC) na-anọchite anya ihe karịrị 80% nke ọrịa cancer akpa ume niile, na-egosipụta mkpa ngwa ngwa maka usoro ọgwụgwọ ezubere iche na nke dị irè.
Mgbanwe EGFR apụtala dị ka isi nkuku na ọgwụgwọ ahaziri onwe nke NSCLC. EGFR tyrosine kinase inhibitors (TKIs) na-enye usoro mgbanwe site n'igbochi mgbaàmà na-akwọ ụgbọala, na-egbochi uto tumor, na ịkwalite ọnwụ mkpụrụ ndụ kansa - niile na-ebelata mmebi nke mkpụrụ ndụ ahụike.
Ntuziaka ụlọ ọgwụ na-eduga, gụnyere NCCN, na-enye iwu ugbu a ịnwale mgbanwe mgbanwe EGFR tupu ịmalite ọgwụgwọ TKI, na-ahụ na ndị ọrịa kwesịrị ekwesị na-enweta ọgwụ ziri ezi site na mmalite.
Mgbanwe EGFR apụtala dị ka isi nkuku na ọgwụgwọ ahaziri onwe nke NSCLC. EGFR tyrosine kinase inhibitors (TKIs) na-enye usoro mgbanwe site n'igbochi mgbaàmà na-akwọ ụgbọala, na-egbochi uto tumor, na ịkwalite ọnwụ mkpụrụ ndụ kansa - niile na-ebelata mmebi nke mkpụrụ ndụ ahụike.
Ntuziaka ụlọ ọgwụ na-eduga, gụnyere NCCN, na-enye iwu ugbu a ịnwale mgbanwe mgbanwe EGFR tupu ịmalite ọgwụgwọ TKI, na-ahụ na ndị ọrịa kwesịrị ekwesị na-enweta ọgwụ ziri ezi site na mmalite.
Na-ewebata ngwa nchọpụta EGFR Gene 29 nke mmadụ (Fluorescence PCR)
Nchọpụta nkenke maka mkpebi ọgwụgwọ ntụkwasị obi
Ngwa nchọpụta EGFR nke Macro & Micro-Test na-enyere aka ịmata ngwa ngwa na nke ziri ezi nke mmụgharị igodo 29 gafee exons 18-21 na anụ ahụ na biopsies mmiri mmiri - na-enye ndị ụlọ ọgwụ ike ịkwado ọgwụgwọ na ntụkwasị obi.
Gịnị mere HọrọMacro & Micro-Nnwale'sNgwa ule EGFR?
Ngwa ahụ na-achọpụta mmụgharị mkpụrụ ndụ EGFR 29 na-ahụkarị na exons 18-21 sitere na anụ ahụ ma ọ bụ ihe nlele ọbara nke ndị ọrịa NSCLC, na-ekpuchi mmetụta ọgwụ na saịtị mgbochi iji duzie iji ọgwụ ezubere iche dị ka gefitinib na osimertinib.
- 1.Imelite ARMS Technology: Emelitere ARMS na nkwalite ikike patent maka nkọwa dị elu;
- 2.Enzymatic Enrichment: Na-ebelata ọdịdị anụ ọhịa site na mgbaze enzymatic, na-emezi nchọpụta nchọpụta ziri ezi ma na-ebelata mmụba na-enweghị isi n'ihi nnukwu ọdịdị genomic;
- 3.Temperature Blocking: Na-agbakwụnye usoro okpomọkụ dị iche iche na usoro PCR, na-ebelata mismatches na ịba ụba nchọpụta ziri ezi;
- 4.High Sensitivity: Na-achọpụta mgbanwe dị ka 1% mutation;
- 5.Great Accuracy: Njikwa ime na UNG enzyme iji belata nsonaazụ ụgha;
- 6.Efficiency: Ebumnuche ebumnuche n'ime 120 min
- 7.Dual Sample Nkwado - Kachasị mma maka ma anụ ahụ na ọbara, na-enye mgbanwe na omume ụlọ ọgwụ.
- 8.Wide ndakọrịta: Dakọtara na ngwá ọrụ PCR bụ isi na ahịa;
- 9.Shelf-ndụ: ọnwa 12.
Usoro ọgwụgwọ na ntụkwasị obi
Ngwa ahụ na-enyere aka ịbawanye nsonaazụ ụlọ ọgwụ wee nọrọ n'ihu nguzogide site na ngbanwe dị oke mkpa na nguzogide.
Gbasaa Pọtụfoliyo Oncology nkenke gị
Chọgharịa usoro nchọpụta mmụgharị anyị zuru oke maka KRAS, BRAF, ROS1, ALK, BCR-ABL, TEL-AML1 na ndị ọzọ-ha niile emebere iji kwado nlekọta nke biomarker zuru oke.
Mụtakwuo:https://www.mmtest.com/oncology/
Contact our team: marketing@mmtest.com
Oge nzipu: Sep-23-2025